Company / R&D per Share
CRISPR Therapeutics AG R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.97
FY2025
5-year range
$2.97 / $5.88
FY2021-FY2025
Trend
-17.9%
vs FY2024
Sector context
#69 of 208
Health Care
What the data says
At $2.97, CRISPR Therapeutics AG's r&d per share ranks #69 of 208 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $5.88 in FY2022 to $2.97 in FY2025.
Based on SEC 10-K filings.
2.97 in FY2025 with a 5-year CAGR of -0.2%.
Declined from $4.84 to $2.97 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -20.4%
- 5-Year CAGR
- -0.2%
- 10-Year CAGR
- -
Sector benchmark
#69 of 208 in Health CareTop 33% of 208This company $2.97 Sector average $28.77
▼
-89.7% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 17.9% year-over-year.
- Ranks #69 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.97 | -17.9% |
| FY2024 | $3.62 | -25.2% |
| FY2023 | $4.84 | -17.7% |
| FY2022 | $5.88 | +32.9% |
| FY2021 | $4.42 | +47.7% |
| FY2020 | $3.00 | -13.4% |
| FY2019 | $3.46 | +232.4% |
| FY2018 | $1.04 | +228.7% |
| FY2017 | $0.32 | +15.7% |
| FY2016 | $0.27 | -89.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026